Organization
BeyondSpring Pharmaceuticals, Inc.
6 abstracts
Abstract
Plinabulin to shorten neutropenia and improve quality of life peri-autologous hematopoietic cell transplant.Org: Adult Bone Marrow Transplant Service, Department of Medicine, Icahn School of Medicine at Mount Sinai, Memorial Sloan Kettering Cancer Center, Myeloma Service, BeyondSpring Pharmaceuticals, Inc.,
Abstract
Real-world response rates and clinical outcomes of patients treated with first-line (1L) platinum-based chemotherapy (PBC) in advanced urothelial cancer (aUC).Org: Kaiser Permanente Oakland Medical Center, Inova Schar Cancer Institute, Pfizer, Genesis Research, EMD Serono Research & Development Institute,
Abstract
Safety, tolerability, and quality of life (QoL) of single-agent plinabulin (Plin) for the prevention of docetaxel (Doc) chemotherapy (chemo)-induced neutropenia (CIN) in non-small cell lung cancer (NSCLC) patients (pts) from two randomized trials.Org: Stanford Cancer Institute, BeyondSpring Pharmaceuticals, Inc.,
Abstract
Prognostic value of baseline immune suppressive biomarkers to select non-small cell lung cancer (NSCLC) patients (pts) likely to benefit from the plinabulin/docetaxel (Plin/Doc) combination.Org: Piedmont Cancer Institue, BeyondSpring Pharmaceuticals, Inc.,
Abstract
Mechanism-based peripheral blood biomarkers to evaluate anticancer effects of the plinabulin/docetaxel combination (plin/doc) vs. doc alone in second/third line EGFR wild-type (WT) NSCLC.Org: Piedmont Cancer Institue, Atlanta Cancer Care, Galderma R&D, BeyondSpring Pharmaceuticals, Inc., NewYork-Presbyterian Brooklyn Methodist Hospital,
Abstract
Prevention of chemotherapy-induced neutropenia (CIN) with plinabulin (Plin) vs placebo (Plac) in patients (pts) with non-small cell lung cancer (NSCLC) treated with docetaxel (Doc): A pooled analysis from 3 randomized trials.Org: Stanford Cancer Institute, Stanford, CA, BeyondSpring Pharmaceuticals, Inc., New York, NY, Newyork, NY,